Marco A Magalhaes1,2, Jamil R Cade1,2. 1. Hospital Santa Marcelina - Cardiologia Intervencionista, São Paulo, SP - Brazil. 2. Faculdade Santa Marcelina - Escola de Medicina, São Paulo, SP - Brazil.
Cardiovascular disease and particularly coronary artery disease (CAD) remain a global
health issue,[1] notwithstanding major
advances in cardiovascular care that have resulted in a reduction in CAD mortality over
the last decades.[2] Indeed, the most
recent trends point towards a bottoming out of CAD mortality rates and, for certain
subgroups, rates might even be increasing.[3] The reasons for these alarming trends relate to the prevalence of
risk factors, health care system failures in dealing with chronic diseases, unequal
access to technology, decreasing levels of investment in cardiovascular research, and
persistent heterogeneity in the quality of care.[4]In contrast, cardiovascular health care costs continue to follow a linear upward
trend.[5] As a consequence, the
delivery of high-value cardiovascular care has been reduced.[6] In the long run, cardiovascular research and innovation
should stimulate the development of novel drugs and therapies. In the short term, for
struggling health care systems facing escalating costs, avoiding inappropriate tests and
ineffective therapies is part of a value-based healthcare agenda.[7,8]
The fundamental concept of moving from volume to value may mitigate conflicting
expectations among payers, providers, patients and physicians, who should share a common
objective of reducing unwarranted health costs while improving outcomes.[9]However, it is time for this agenda to be transformed from discussion into action. Taking
the lead in this transformation over the last decade, physicians representing the North
American medical societies have come together to provide evidence-based recommendations
and expert opinions for a range of diagnostic and therapeutic procedures. These evolving
recommendations, namely Appropriate Use Criteria (AUC), aim to assist physicians in
providing high-value cardiovascular care.In this issue of Arquivos Brasileiros de Cardiologia, Luciano et al.[10] present results on the use of AUC for
diagnostic catheterization (DC) in Brazil.[10] From May to October 2016, data were obtained for DC performed at
two tertiary hospitals (a general hospital vs. a cardiology hospital). The authors
collected data that allowed appropriateness scores to be assigned for each DC, namely,
"appropriate" (7 to 9), "occasionally appropriate" (4 to 6) or "rarely appropriate" (1
to 3). Of note, according to the original AUC, the same scoring system was used, but the
descriptive terms used were "appropriate", "uncertain" and "inappropriate",
respectively.[11] Additionally,
the authors compared each of the three AUC categories between hospitals and with the
presence of CAD. The presence of obstructive CAD was defined as angiographic obstruction
of more than 50% in the left main coronary artery or 70% elsewhere.The sample included 737 DC in patients with a mean age of 62 years. Taken together, 80.6%
of the exams were deemed appropriate according to AUC criteria, and 15.1% occasionally
appropriate (uncertain), while 4.3% were rarely appropriate (inappropriate). Among
similar studies, the rates of appropriate, uncertain and inappropriate use of diagnostic
catheterization were 52.8%, 31% and 10.8% in Ontario, and 35%, 40% and 25% in New York,
respectively.[12,13] Notably, in the Brazilian study, the
rate of inappropriate use in stable patients only (~10.1%) was similar to that in the
Ontario cohort (10.8%) and roughly two-fold lower than in the US study. Interestingly,
both Canada and Brazil have public universal health systems, which differ from that in
the United States, where the health system is predominately financed by private
funds.[9]The second finding that deserves careful attention is the lack of severe obstructive CAD
in 41.2% of DC. Although this frequency is lower than that in the Canadian cohort
(54.5%), it stills represents an important source of cardiovascular expenditure that can
be improved through a comprehensive and specialized assessment (pre-test probability).
Indeed, the frequency of normal DC findings was significantly lower at the specialized
cardiology hospital than at the general hospital (37.8% vs. 52.6%; p = 0.008), despite a
three-times higher volume at the former. Moreover, among patients under CAD
investigation, the rates of appropriate DC were significantly higher at the cardiology
hospital compared with the general hospital (87.3% vs. 58.5%; p < 0.01). Therefore,
these results constitute indirect evidence of higher quality performance in high-volume
and specialized centers of cardiovascular care.There are a number of caveats relating to the study. First, the sample size was
relatively small. Second, the AUC categorization was made by the same non-blinded
physician who performed the DC and participated in the final decision on whether to
proceed with intervention. Third, neither baseline risk factors nor stress test findings
were reported, particularly for the general hospital that had a higher proportion of CAD
investigation (stable patients) compared with cardiology hospital (73% vs. 34%) Fourth,
there was a lack of functional and intravascular invasive imaging assessments. Finally,
the sample included only patients from the public health system and clinical outcomes
were not presented.A further interesting finding of Luciano et al.[10] relates to the reasons behind the rarely appropriate
(inappropriate) category of DC and the decision-making upstream. The higher the
frequency of inappropriate DC, the more likely the frequency of further inappropriate
interventions, a phenomenon called the "diagnostic-therapeutic cascade".[14] The danger of this cascade was averted
in the two Brazilian hospitals, however, where ALL patients rated as receiving an
inappropriate DC, 21.9% of whom had severe obstructive CAD, remained under clinical
treatment, which was carried out according to the best evidence available. We commend
the authors and physicians for "doing the right things AND doing things right", thus
benefiting patients and the health care system.
Authors: Manesh R Patel; Steven R Bailey; Robert O Bonow; Charles E Chambers; Paul S Chan; Gregory J Dehmer; Ajay J Kirtane; L Samuel Wann; R Parker Ward Journal: J Am Coll Cardiol Date: 2012-05-09 Impact factor: 24.094
Authors: Hamilton Moses; David H M Matheson; E Ray Dorsey; Benjamin P George; David Sadoff; Satoshi Yoshimura Journal: JAMA Date: 2013-11-13 Impact factor: 56.272
Authors: Edward L Hannan; Zaza Samadashvili; Kimberly Cozzens; Gary Walford; David R Holmes; Alice K Jacobs; Nicholas J Stamato; Ferdinand J Venditti; Samin Sharma; Spencer B King Journal: Circ Cardiovasc Interv Date: 2014-01-28 Impact factor: 6.546
Authors: Luis Sérgio Carvalho Luciano; Roberto Léo da Silva; Ozir Miguel Londero Filho; Leandro Waldrich; Luciano Panata; Ana Paula Trombetta; Julio Cesar Preve; Tammuz Fattah; Luiz Carlos Giuliano; Luiz Eduardo Koenig São Thiago Journal: Arq Bras Cardiol Date: 2019-03-14 Impact factor: 2.000
Authors: Karam Sadoon Alzuhairi; Peter Søgaard; Jan Ravkilde; Gunnar Gislason; Lars Køber; Christian Torp-Pedersen Journal: Eur Heart J Qual Care Clin Outcomes Date: 2015-11-01
Authors: Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell Journal: N Engl J Med Date: 2007-06-07 Impact factor: 91.245
Authors: Nihar R Desai; Lesli S Ott; Elizabeth J George; Xiao Xu; Nancy Kim; Shengfan Zhou; Angela Hsieh; Sudhakar V Nuti; Zhenqiu Lin; Susannah M Bernheim; Harlan M Krumholz Journal: JAMA Netw Open Date: 2018-10-05